144 related articles for article (PubMed ID: 11585241)
1. Posttransplant cardiovascular risk: impact on long-term patient survival. Introduction.
Vanrenterghem Y
Transplantation; 2001 Sep; 72(6 Suppl):S4. PubMed ID: 11585241
[No Abstract] [Full Text] [Related]
2. Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population.
First MR
Transplantation; 2001 Sep; 72(6 Suppl):S20-4. PubMed ID: 11585240
[TBL] [Abstract][Full Text] [Related]
3. Graft function and other risk factors as predictors of cardiovascular disease outcome.
Forsythe JL
Transplantation; 2001 Sep; 72(6 Suppl):S16-9. PubMed ID: 11585239
[TBL] [Abstract][Full Text] [Related]
4. Steroid withdrawal in renal transplant recipients.
Oppenheimer F
Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
[No Abstract] [Full Text] [Related]
5. [Transplant ok--patient ko?].
Wepner U
MMW Fortschr Med; 2004 Sep; 146(39):4-5. PubMed ID: 15532404
[No Abstract] [Full Text] [Related]
6. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.
Neuberger JM; Bechstein WO; Kuypers DR; Burra P; Citterio F; De Geest S; Duvoux C; Jardine AG; Kamar N; Krämer BK; Metselaar HJ; Nevens F; Pirenne J; Rodríguez-Perálvarez ML; Samuel D; Schneeberger S; Serón D; Trunečka P; Tisone G; van Gelder T
Transplantation; 2017 Apr; 101(4S Suppl 2):S1-S56. PubMed ID: 28328734
[TBL] [Abstract][Full Text] [Related]
7. [Immunosuppression and its use in kidney transplantation].
Paliege A; Bamoulid J; Bachmann F; Staeck O; Halleck F; Khadzhynov D; Brakemeier S; Dürr M; Budde K
Urologe A; 2015 Oct; 54(10):1376-84. PubMed ID: 26459580
[TBL] [Abstract][Full Text] [Related]
8. [Post-transplantation diabetes mellitus].
Yamada K
Nihon Jinzo Gakkai Shi; 2004; 46(8):781-8. PubMed ID: 15645733
[No Abstract] [Full Text] [Related]
9. Risk factors for chronic graft dysfunction in 918 renal transplants.
Mota A; Figueiredo A; Macário F; Cunha FX; Freitas L; Parada B; Bastos C; Furtado L
Transplant Proc; 2003 May; 35(3):1064-5. PubMed ID: 12947857
[No Abstract] [Full Text] [Related]
10. [Discontinuing immunosuppression due to annoying hirsutism. Noncompliance is the number 1 etiology of graft rejection].
MMW Fortschr Med; 2004 Sep; 146(39):8, 10. PubMed ID: 15532405
[No Abstract] [Full Text] [Related]
11. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
[TBL] [Abstract][Full Text] [Related]
12. Excessive immunosuppression in kidney transplant patients: prevalence and outcomes.
Sanders-Pinheiro H; da Silveira ST; Carminatti M; Braga LS; Marsicano EO; Magalhães GL; Carvalho LF; Filho GF; Magacho EJ; Colugnati F; Bastos MG
Transplant Proc; 2012 Oct; 44(8):2381-3. PubMed ID: 23026599
[TBL] [Abstract][Full Text] [Related]
13. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
[No Abstract] [Full Text] [Related]
14. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation.
Schweer T; Gwinner W; Scheffner I; Schwarz A; Haller H; Blume C
Clin Transplant; 2014 Apr; 28(4):512-9. PubMed ID: 24649873
[TBL] [Abstract][Full Text] [Related]
15. Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients.
Boucher A; Masse M; Lauzon L; Morin M; Dandavino R
Transplant Proc; 2002 Aug; 34(5):1799-802. PubMed ID: 12176582
[No Abstract] [Full Text] [Related]
16. New-onset diabetes after transplantation: a review of recent literature.
Balla A; Chobanian M
Curr Opin Organ Transplant; 2009 Aug; 14(4):375-9. PubMed ID: 19542891
[TBL] [Abstract][Full Text] [Related]
17. Targeting cardiovascular risk in renal transplantation.
Kiberd BA; West KA
Transplant Proc; 2001; 33(1-2):1117-8. PubMed ID: 11267217
[No Abstract] [Full Text] [Related]
18. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
Akiyama T; Okazaki H; Takahashi K; Hasegawa A; Tanabe K; Uchida K; Takahara S; Toma H
Transplant Proc; 2005 Mar; 37(2):843-5. PubMed ID: 15848551
[No Abstract] [Full Text] [Related]
19. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
[No Abstract] [Full Text] [Related]
20. Patient Preferences for Outcomes After Kidney Transplantation: A Best-Worst Scaling Survey.
Howell M; Wong G; Rose J; Tong A; Craig JC; Howard K
Transplantation; 2017 Nov; 101(11):2765-2773. PubMed ID: 29064956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
